Infusion Reactions Following Re-administration In a clinical trial of patients with moderate to severe Ps designed to assess the efficacy of long-termmaintenance therapyversus re-treatment with an induction regimen of Infliximab following disease flare, 4% (8/219) of patients in the re-treatmentind...
The long-term effects of the drug are not known. The drug may reactivate latent tuberculosis. The relationship with plasma cell dyscrasias and lymphoproliferative diseases remains unexplained. CLINICAL IMPLICATIONS: Infliximab may be used as an effective therapeutic agent for patients with sarcoidosis who...
Long-term studies will be required to characterize further the safety risks associated with TNF-α antagonists. Switching among TNF-α antagonists Although it has not been studied in patients with PsA, it has been shown in patients with RA and spondyloarthropathy that a reasonable approach to use...
The clinical significance of apparent increased immunogenicity on efficacy and infusion reactions in Ps patients as compared to patients with other diseases treated with REMICADE over the long term is not known. Immunogenicity in Pediatric Patients with Crohn's Disease In Study Peds Crohn's, in ...
executive vice president of Global Commercial Operations at Amgen. "Following July's exciting launches of our two biosimilars in oncology, Avsola highlights Amgen's long-term commitment to providing more affordable biological treatment options to patients across critical disease states, including chronic ...
Long-term studies will be required to characterize further the safety risks associated with TNF-α antagonists. Switching among TNF-α antagonists Although it has not been studied in patients with PsA, it has been shown in patients with RA and spondyloarthropathy that a reasonable approach to use...